GlassScriptPhysician profile
Sanjay Sikand
NPI 1225119415
$11,895.31
in general payments reported to CMS, 2019-2025
39 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $717 · 2021: $1,065 · 2022: $2,732 · 2023: $2,382 · 2024: $1,848 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,630 · Travel and Lodging: $195 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,629.97 |
| Travel and Lodging | $195.00 |
| Education | $165.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,468.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,100.26 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Astrazeneca Uk Limited | $1,231.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.21 | 2019-2025 | Ofev |
| Mylan Specialty L.P. | $660.76 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $658.91 | 2022-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $619.40 | 2019-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $409.89 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $384.79 | 2019-2025 | Dupixent |
| Insmed, INC. | $298.49 | 2021-2025 | Arikayce |
| Philips North America LLC | $239.87 | 2019-2023 | |
| Viatris Specialty LLC | $199.86 | 2025 | Yupelri |
| Inari Medical, INC. | $183.43 | 2022 | |
| Genentech USA, INC. | $169.78 | 2019 | |
| Harmony Biosciences LLC | $166.72 | 2021-2025 | Wakix |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $153.75 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $135.88 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.29 | 2024 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $114.37 | 2023-2024 | Cuvitru, Aralast, Hyqvia |
| Amgen INC. | $112.21 | 2023-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $95.97 | 2023-2025 | Lumryz |
| Electromed, INC. | $87.91 | 2022-2024 | Smartvest |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Sunovion Pharmaceuticals INC. | $71.11 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.98 | 2019-2023 | |
| United Therapeutics Corporation | $57.77 | 2019-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $50.76 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $45.14 | 2019-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $39.96 | 2022-2023 | Acthar |
| Idorsia Pharmaceuticals US INC | $29.84 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $27.19 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $23.11 | 2019 | |
| Lilly USA, LLC | $19.37 | 2025 | Zepbound |
| Pulmonx Corporation | $15.27 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Circassia INC. | $13.93 | 2020 | |
| Zoll Respicardia, INC. | $13.75 | 2025 | Remede System |
| Vifor Pharma, INC. | $13.27 | 2024 | Zemaira |
| Pfizer INC. | $13.07 | 2020 | |
| Shire North American Group INC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sikand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.